Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Follow-on Biologics: Rep. Eshoo Revising Her Bill To Be Closer To Senate Provision

This article was originally published in The Pink Sheet Daily

Executive Summary

California Democrat drops data exclusivity to 12 years, plus six months for pediatric studies, and removes requirement for FDA guidance before approval.
Advertisement

Related Content

Biosimilar Guidance: Brands Try Again For A Pre-Approval Requirement
Biosimilar Guidance: Brands Try Again For A Pre-Approval Requirement
Follow-on Biologics Showdown In House Set For July 17
Sen. Brown Vows Floor Fight On Follow-on Biologics
Follow-on Biologics Go Back To The Future: Senate Cmte. Endorses 12 Years of Brand Exclusivity
Follow-on Biologics Go Back To The Future: Senate Cmte. Endorses 12 Years of Brand Exclusivity

Topics

Advertisement
UsernamePublicRestriction

Register

PS069707

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel